What medications are recommended for the treatment of acute subarachnoid hemorrhage?

Medications for Acute Subarachnoid Hemorrhage Treatment

Give oral nimodipine 60 mg every 4 hours (6 times daily) to all patients with aneurysmal subarachnoid hemorrhage—this is the only medication with proven benefit for improving neurological outcomes and reducing death and dependency. 1, 2

Core Pharmacologic Management

Nimodipine (Class I, Level A Evidence)

• Dosing: 60 mg orally every 4 hours for 21 days
• Mechanism: Calcium channel blocker that improves neurological outcomes (NOT by preventing vasospasm, but through neuroprotection)
• Administration: Must be given enterally—oral or via nasogastric/feeding tube
• Critical point: If hypotension occurs, manage it with vasopressors rather than stopping nimodipine, as consistent administration correlates with reduced delayed cerebral ischemia 2, 3
• Common barrier: 99% of patients experience treatment interruptions; ensure continuation during transfers between facilities 3

Blood Pressure Control (Class I, Level B Evidence)

From symptom onset until aneurysm is secured:

• Target systolic BP <160 mmHg 1
• Use titratable IV agents (nicardipine preferred over labetalol for smoother control) 1
• Balance rebleeding risk against maintaining cerebral perfusion pressure
• After aneurysm secured and if vasospasm develops: Consider induced hypertension 2

Antifibrinolytic Therapy (Class IIa, Level B Evidence)

Only if unavoidable delay in aneurysm treatment:

• Tranexamic acid OR aminocaproic acid
• Duration: <72 hours maximum
• Purpose: Reduce early rebleeding risk
• Caution: Increased deep venous thrombosis risk 1

What NOT to Give

Medications Without Proven Benefit (Class III Evidence)

• Statins: No improvement in outcomes despite early promise 2, 4
• Intravenous magnesium: Failed to show neurological benefit 2, 4
• Clazosentan (endothelin receptor antagonist): No functional outcome improvement 4, 5
• Other calcium channel blockers (IV or other oral forms): Uncertain value 1
• Prophylactic hypervolemia: Associated with worse outcomes and complications 2

Seizure Prophylaxis (Class IIb, Level B Evidence)

• May consider short-term prophylactic anticonvulsants in immediate post-hemorrhage period
• Do NOT use routine long-term prophylaxis 1, 6
• If used, levetiracetam preferred over phenytoin (phenytoin associated with worse cognitive outcomes at 3 months) 1
• Consider only for high-risk patients: prior seizure, intracerebral hematoma, middle cerebral artery aneurysm, or infarction 1

Supportive Medical Management

Euvolemia Maintenance (Class I, Level B Evidence)

• Target normal circulating blood volume, NOT hypervolemia 1, 2
• Use crystalloid infusions
• Central venous pressure alone unreliable—consider advanced hemodynamic monitoring 2

Hyponatremia Management

• Cerebral salt wasting common (10-30% incidence)
• Consider 3% hypertonic saline for correction 1
• Fludrocortisone may help correct negative sodium balance 1

Critical Pitfalls to Avoid

1. Aspirin/antiplatelet agents: Absolutely contraindicated in acute SAH (these recommendations are for ischemic stroke only) 7
2. Delaying nimodipine: Start immediately upon diagnosis—delays from hospital transfers are the most common reason for suboptimal treatment 3
3. Stopping nimodipine for hypotension: Manage BP with vasopressors instead; interruptions increase delayed cerebral ischemia risk 2, 3
4. Prophylactic hypervolemia: Outdated "triple-H therapy" approach—causes harm 2, 5, 8
5. IV nimodipine: Limited data; oral/enteral route is standard 2

Treatment Algorithm Priority

1. Immediate: Oral nimodipine 60 mg q4h
2. Immediate: IV titratable antihypertensive (target SBP <160 mmHg until aneurysm secured)
3. If transfer delay >24-72h: Consider short-term antifibrinolytic
4. Optional: Short-term seizure prophylaxis (levetiracetam) in immediate period only
5. Continuous: Maintain euvolemia with crystalloids
6. Avoid: Statins, magnesium, prophylactic hypervolemia, long-term anticonvulsants

The evidence strongly supports that nimodipine is the cornerstone of medical management, while most other pharmacologic interventions have failed to demonstrate benefit in rigorous trials 1, 2, 4.